<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00461032</url>
  </required_header>
  <id_info>
    <org_study_id>0476-340</org_study_id>
    <secondary_id>MK0476-340</secondary_id>
    <secondary_id>2007_539</secondary_id>
    <nct_id>NCT00461032</nct_id>
  </id_info>
  <brief_title>Montelukast Back to School Asthma Study (0476-340)</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind, Placebo-Controlled Parallel Group 8-week Study to Evaluate the Efficacy and Safety of Chewable Montelukast When Initiated at the Start of the School Year in Pediatric Patients With Chronic Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study, in children with chronic asthma, evaluates the number of days of worsening asthma
      during 8 weeks of treatment with montelukast after treatment is started for the first day of
      school.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">November 2006</completion_date>
  <primary_completion_date type="Actual">November 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Percentage of Days With Worsening Asthma (as Measured on Daily Diaries) in Pediatric Asthmatic Participants</measure>
    <time_frame>8 Week treatment period initiated at the beginning of a school year</time_frame>
    <description>A day of worsening asthma is a day with: increase from baseline in β-agonist use (&gt; 70% and a min increase of 2 puffs); &gt; 50% increase from baseline in daytime symptoms score; awake &quot;all night&quot;; increase from baseline in inhaled corticosteroid use ≥ 100% or oral corticosteroid rescue for worsening asthma; or unanticipated healthcare utilization.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With the Occurrence of One or More Health Care Utilizations (as Measured on Daily Diaries)</measure>
    <time_frame>8 Week treatment period initiated at the beginning of a school year</time_frame>
    <description>Health care utilization is defined as unanticipated asthma care in an office or clinic, emergent or hospital setting.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Days With Increased β-agonist Use by &gt;70% and a Minimum Increase of 2 Puffs From Baseline (as Measured on Daily Diaries) in Pediatric Asthmatic Participants</measure>
    <time_frame>8 Week treatment period initiated at the beginning of a school year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Days With Increased Daytime Asthma Symptom Score by &gt;50% From Baseline (as Measured on Daily Diaries) in Pediatric Asthmatic Participants</measure>
    <time_frame>8 Week treatment period initiated at the beginning of a school year</time_frame>
    <description>Daytime asthma symptom score was calculated as the sum of the responses (0 (best) to 5 (worst)) to three daytime symptom questions.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1162</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>montelukast</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>montelukast</intervention_name>
    <description>montelukast 5 mg tablet Once a day (QD) for 8 weeks</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: Placebo</intervention_name>
    <description>Placebo to montelukast QD for 8 weeks</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female non-smoking Participants, ages 6 to 14 years, with chronic asthma,
             history of at least one asthma exacerbation associated with a cold within the past
             year and a documented history of asthma that required treatment with any asthma
             medication within 6 months prior to Visit 1

        Exclusion Criteria:

          -  Participant cannot have any other acute or chronic pulmonary disorder, or
             hospitalization for asthma more than three times within one year prior to signing
             informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>14 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>MedWatch - FDA maintained medical product safety Information</description>
  </link>
  <link>
    <url>http://www.merck.com/product/patients_caregivers/home.html</url>
    <description>Merck: Patient &amp; Caregiver U.S. Product Web Site</description>
  </link>
  <reference>
    <citation>Weiss KB, Gern JE, Johnston NW, Sears MR, Jones CA, Jia G, Watkins MW, Smugar SS, Edelman JM, Grant EN. The Back to School asthma study: the effect of montelukast on asthma burden when initiated prophylactically at the start of the school year. Ann Allergy Asthma Immunol. 2010 Aug;105(2):174-81. doi: 10.1016/j.anai.2010.04.018. Epub 2010 Jul 1.</citation>
    <PMID>20674830</PMID>
  </reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 13, 2007</study_first_submitted>
  <study_first_submitted_qc>April 13, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 17, 2007</study_first_posted>
  <results_first_submitted>January 12, 2010</results_first_submitted>
  <results_first_submitted_qc>January 12, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 4, 2010</results_first_posted>
  <last_update_submitted>January 19, 2017</last_update_submitted>
  <last_update_submitted_qc>January 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Montelukast</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were randomized at 165 sites in the US and Canada.
Therapy period: June to November 2006 (including screening period).</recruitment_details>
      <pre_assignment_details>Participants who were hospitalized for asthma in the 4 weeks prior to randomization or who required excluded medications were excluded from randomization.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Montelukast matching-image placebo tablet taken orally once daily at bedtime for 8 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Montelukast 5 mg</title>
          <description>Montelukast 5 mg chewable tablet taken orally once daily (OD) at bedtime for 8 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="582"/>
                <participants group_id="P2" count="580"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="545"/>
                <participants group_id="P2" count="536"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="44"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient Moved or Relocated</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not Specified</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Montelukast matching-image placebo tablet taken orally once daily at bedtime for 8 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Montelukast 5 mg</title>
          <description>Montelukast 5 mg chewable tablet taken orally once daily (OD) at bedtime for 8 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="582"/>
            <count group_id="B2" value="580"/>
            <count group_id="B3" value="1162"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.9" spread="2.5"/>
                    <measurement group_id="B2" value="9.9" spread="2.4"/>
                    <measurement group_id="B3" value="9.9" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="236"/>
                    <measurement group_id="B2" value="225"/>
                    <measurement group_id="B3" value="461"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="346"/>
                    <measurement group_id="B2" value="355"/>
                    <measurement group_id="B3" value="701"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Daytime Asthma Symptom Score</title>
          <description>The Participant or parent/guardian scored his/her/child's symptoms [from 0 (best) to 5 (worst)] on a daily basis. Scores were entered into a Participant diary during the 2-week period prior to the start of the study drug.</description>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.32" spread="1.81"/>
                    <measurement group_id="B2" value="1.35" spread="1.94"/>
                    <measurement group_id="B3" value="1.34" spread="1.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>β-Agonist Use</title>
          <description>The number of puffs used per day was entered by the Participant or parent/guardian into a Participant diary during the 2-week period prior to the start of the study drug.</description>
          <units>puffs/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.62" spread="1.11"/>
                    <measurement group_id="B2" value="0.54" spread="0.94"/>
                    <measurement group_id="B3" value="0.58" spread="1.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Percentage of Days With Worsening Asthma (as Measured on Daily Diaries) in Pediatric Asthmatic Participants</title>
        <description>A day of worsening asthma is a day with: increase from baseline in β-agonist use (&gt; 70% and a min increase of 2 puffs); &gt; 50% increase from baseline in daytime symptoms score; awake &quot;all night&quot;; increase from baseline in inhaled corticosteroid use ≥ 100% or oral corticosteroid rescue for worsening asthma; or unanticipated healthcare utilization.</description>
        <time_frame>8 Week treatment period initiated at the beginning of a school year</time_frame>
        <population>The primary efficacy analysis was based on full-analysis-set (FAS) population. This included all randomized participants who received at least one dose of double-blinded therapy and had a valid efficacy measurement. The percent of worsening asthma days was calculated from at least 7 days of diary data. Missing diary data were not imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Montelukast matching-image placebo tablet taken orally once daily at bedtime for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Montelukast 5 mg</title>
            <description>Montelukast 5 mg chewable tablet taken orally once daily (OD) at bedtime for 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percentage of Days With Worsening Asthma (as Measured on Daily Diaries) in Pediatric Asthmatic Participants</title>
          <description>A day of worsening asthma is a day with: increase from baseline in β-agonist use (&gt; 70% and a min increase of 2 puffs); &gt; 50% increase from baseline in daytime symptoms score; awake &quot;all night&quot;; increase from baseline in inhaled corticosteroid use ≥ 100% or oral corticosteroid rescue for worsening asthma; or unanticipated healthcare utilization.</description>
          <population>The primary efficacy analysis was based on full-analysis-set (FAS) population. This included all randomized participants who received at least one dose of double-blinded therapy and had a valid efficacy measurement. The percent of worsening asthma days was calculated from at least 7 days of diary data. Missing diary data were not imputed.</population>
          <units>Percentage of Days</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="499"/>
                <count group_id="O2" value="499"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.23" lower_limit="24.25" upper_limit="30.00"/>
                    <measurement group_id="O2" value="24.26" lower_limit="21.52" upper_limit="27.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With the Occurrence of One or More Health Care Utilizations (as Measured on Daily Diaries)</title>
        <description>Health care utilization is defined as unanticipated asthma care in an office or clinic, emergent or hospital setting.</description>
        <time_frame>8 Week treatment period initiated at the beginning of a school year</time_frame>
        <population>The analysis was based on the FAS population. This included all randomized participants who received at least 1 dose of study medication and had a valid efficacy measurement. Occurrence of one or more health care utilization was derived from the available diary data and was set to missing if no diary data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Montelukast matching-image placebo tablet taken orally once daily at bedtime for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Montelukast 5 mg</title>
            <description>Montelukast 5 mg chewable tablet taken orally once daily (OD) at bedtime for 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With the Occurrence of One or More Health Care Utilizations (as Measured on Daily Diaries)</title>
          <description>Health care utilization is defined as unanticipated asthma care in an office or clinic, emergent or hospital setting.</description>
          <population>The analysis was based on the FAS population. This included all randomized participants who received at least 1 dose of study medication and had a valid efficacy measurement. Occurrence of one or more health care utilization was derived from the available diary data and was set to missing if no diary data were available.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="476"/>
                <count group_id="O2" value="466"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Participants requiring Health Care Utilization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                    <measurement group_id="O2" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants not requiring Health Care Utilization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="406"/>
                    <measurement group_id="O2" value="411"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Days With Increased β-agonist Use by &gt;70% and a Minimum Increase of 2 Puffs From Baseline (as Measured on Daily Diaries) in Pediatric Asthmatic Participants</title>
        <time_frame>8 Week treatment period initiated at the beginning of a school year</time_frame>
        <population>The secondary efficacy analysis was based on full-analysis-set (FAS) population. This included all randomized participants who received at least one dose of double-blinded therapy and had valid efficacy measurement for at least 7 days of diary data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Montelukast matching-image placebo tablet taken orally once daily at bedtime for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Montelukast 5 mg</title>
            <description>Montelukast 5 mg chewable tablet taken orally once daily (OD) at bedtime for 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Days With Increased β-agonist Use by &gt;70% and a Minimum Increase of 2 Puffs From Baseline (as Measured on Daily Diaries) in Pediatric Asthmatic Participants</title>
          <population>The secondary efficacy analysis was based on full-analysis-set (FAS) population. This included all randomized participants who received at least one dose of double-blinded therapy and had valid efficacy measurement for at least 7 days of diary data.</population>
          <units>Percentage of Days</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="491"/>
                <count group_id="O2" value="495"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.02" lower_limit="5.80" upper_limit="8.23"/>
                    <measurement group_id="O2" value="6.04" lower_limit="4.84" upper_limit="7.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Days With Increased Daytime Asthma Symptom Score by &gt;50% From Baseline (as Measured on Daily Diaries) in Pediatric Asthmatic Participants</title>
        <description>Daytime asthma symptom score was calculated as the sum of the responses (0 (best) to 5 (worst)) to three daytime symptom questions.</description>
        <time_frame>8 Week treatment period initiated at the beginning of a school year</time_frame>
        <population>The secondary efficacy analysis was based on full-analysis-set (FAS) population. This included all randomized participants who received at least one dose of double-blinded therapy and had a valid efficacy measurement. Variables that were measured as the average over the treatment period were defined from at least 7 days of evaluable diary data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Montelukast matching-image placebo tablet taken orally once daily at bedtime for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Montelukast 5 mg</title>
            <description>Montelukast 5 mg chewable tablet taken orally once daily (OD) at bedtime for 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Days With Increased Daytime Asthma Symptom Score by &gt;50% From Baseline (as Measured on Daily Diaries) in Pediatric Asthmatic Participants</title>
          <description>Daytime asthma symptom score was calculated as the sum of the responses (0 (best) to 5 (worst)) to three daytime symptom questions.</description>
          <population>The secondary efficacy analysis was based on full-analysis-set (FAS) population. This included all randomized participants who received at least one dose of double-blinded therapy and had a valid efficacy measurement. Variables that were measured as the average over the treatment period were defined from at least 7 days of evaluable diary data.</population>
          <units>Percentage of Days</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="491"/>
                <count group_id="O2" value="496"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.4" lower_limit="15.33" upper_limit="19.47"/>
                    <measurement group_id="O2" value="16.03" lower_limit="13.99" upper_limit="18.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events (AEs) were collected during the 8 week, double-blind treatment period, and up to and including 14 days after the last dose of study therapy</time_frame>
      <desc>The number of participants listed in the AE tables (566 placebo &amp; 566 montelukast) is the number that received treatment. 16 placebo &amp; 14 montelukast randomized participants did not receive treatment.
Although a participant may have 2 or more AEs they are counted only once in a category. The same participant may appear in other categories.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Montelukast matching-image placebo tablet taken orally once daily at bedtime for 8 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Montelukast 5 mg</title>
          <description>Montelukast 5 mg chewable tablet taken orally once daily (OD) at bedtime for 8 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 9.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="566"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="566"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="566"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="566"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 9.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="189" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="191" subjects_at_risk="566"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="566"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphangioma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="566"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="566"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="566"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Stomach discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="566"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="566"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy to arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="566"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acarodermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Body tinea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Bronchitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Eye infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Hordeolum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Impetigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Labyrinthitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Otitis media acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Pharyngitis streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Pharyngotonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Pneumonia viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="566"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Arthropod sting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Foreign body in eye</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Joint sprain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Neck injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Soft tissue injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="566"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="566"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="566"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Exostosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Joint effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="566"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Sinus headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="566"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Mood swings</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Sleep terror</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="566"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="566"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Nipple pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Nipple swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="566"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Bronchial hyperreactivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Nocturnal dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Sneezing</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="566"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Rash generalised</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Seborrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Skin irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="566"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Endodontic procedure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="566"/>
              </event>
              <event>
                <sub_title>Wisdom teeth removal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="566"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="566"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

